Sildenafil prevents right ventricular hypertrophy and improves heart rate variability in rats with pulmonary hypertension secondary to experimental diabetes

References

• Ala M, Mohammad JR, Dehpour AR. 2021. Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. Fundam Clin Pharmacol. 35(2):235–59. doi:10.1111/fcp.12633
   PubMed Web of Science ®Google Scholar
• Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM. 2008. Chronic administration of Sildenafil improves markers of endothelial function in men with type 2 diabetes. Diabet Med. 25(1):37–44. doi:10.1111/j.1464-5491.2007.02298.x
   PubMed Web of Science ®Google Scholar
• Rashid J, Patel B, Nozik-Grayck E, McMurtry IF, Stenmark KR, Ahsan F. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH). J Control Release. 2017;250:96–106. 10.1016/j.jconrel.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. 2019. An overview of the 6th world symposium on pulmonary hypertension. Eur Respir J. 53(1):1802148. doi:10.1183/13993003.02148-2018
   PubMed Web of Science ®Google Scholar
• Ren Z, Li J, Shen J, Yu H, Mei X, Zhao P, Xiao Z, Wu W. 2020. Therapeutic sildenafil inhibits pulmonary damage induced by cigarette smoke exposure and bacterial inhalation in rats. Pharm Biol. 58(1):116–23. doi:10.1080/13880209.2019.1711135
   PubMed Web of Science ®Google Scholar
• Ogawa M, Ishizaka M, Akabane R, Sakatani A, Nagakawa M, Miyakawa H, Miyagawa Y, Takemura N. 2020. Evaluation of the autonomic nervous system in a canine model of chronic embolic pulmonary hypertension. Vet Res Commun. 44(2):73–81. doi:10.1007/s11259-020-09774-z
   PubMed Web of Science ®Google Scholar
• Semen K, Yelisyeyeva O, Jarocka-Karpowicz I, Kaminskyy D, Solovey L, Skrzydlewska E, Yavorskyi O. Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability. Redox Biol. 2016;7:48–57. 10.1016/j.redox.2015.11.009.
   PubMed Web of Science ®Google Scholar
• Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21. 10.12047/j.cjap.5501.2017.080.
   PubMed Web of Science ®Google Scholar
• Zimmermann LM, Baptista MS, Tardivo JP, Pinhal MA. Type II diabetes patients under sildenafil citrate: case series showing benefits and a side effect. Case Reports in Medicine. 2020;2020:4065452. Published 2020 May 9. doi:10.1016/j.athoracsur.2006.08.051.
   PubMed Web of Science ®Google Scholar
• Roberts TJ, Burns AT, MacIsaac RJ, MacIsaac AI, Prior DL, La Gerche A. 2019. Sildenafil enhances central hemodynamic responses to exercise, but not V o 2peak, in people with diabetes mellitus. J Appl Physiol. 127(1):1–10. doi:10.1152/japplphysiol.00947.2018
   PubMed Web of Science ®Google Scholar
• Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, Ziegler D. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev. 2009 Feb;25(2):136–43. doi:10.1002/dmrr.921. PMID: 19116943.
   PubMed Web of Science ®Google Scholar
• Lang IM, Simonneau G, Pepke-Zaba JW, Mayer E, Ambrož D, Blanco I, Torbicki A, Mellemkjaer S, Yaici A, Delcroix M. 2013. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost. 110(1):83–91. doi:10.1160/TH13-02-0097
   PubMed Web of Science ®Google Scholar
• Khateeb J, Fuchs E, Khamaisi M. 2019. Diabetes and lung disease: A neglected relationship. Rev Diabet Stud. 15(1):1–15. doi:10.1900/RDS.2019.15.1
   PubMedGoogle Scholar
• Moral SJ, Lopez LJG, Menendez C, Moreno E, Barreira B, Morales CD, Escolano L, Fernandez SP, Villamor E, Cogolludo A, et al. Different patterns of pulmonary vascular disease induced by type 1 diabetes and moderate hypoxia in rats. Exp Physiol. 2012;97(5):676–86. doi:10.1113/expphysiol.2011.062257.
   PubMed Web of Science ®Google Scholar
• Lopez LJG, Moral SJ, Frazziano G, Gomez VMJ, Moreno L, Menendez C, Flores HJ, Lorente JA, Cogolludo A, Perez VF. 2011. Type 1 diabetes-induced hyper-responsiveness to 5-hydroxytryptamine in rat pulmonary arteries via oxidative stress and induction of cyclooxygenase-2. J Pharmacol Exp Ther. 338(1):400–07. doi:10.1124/jpet.111.179515
   PubMed Web of Science ®Google Scholar
• López LG, Tepox GAY, Atonal FF, Flores HJ, Pérez VF, Villa MAE, Miguél GG, Reynoso PA. 2021. Echocardiographic follow-up to right ventricular modifications in secondary pulmonary hypertension to diabetes in rats. Clin Exp Hypertens. 43(3):242–53. doi:10.1080/10641963.2020.1860077
   PubMed Web of Science ®Google Scholar
• Norma Oficial Mexicana NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio (technical specifications for the production, care and use of laboratory animals). DOF; 2001. México.
   Google Scholar
• Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H. 2004. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 169(1):34–38. doi:10.1164/rccm.200303-346OC
   PubMed Web of Science ®Google Scholar
• Alsalahi A, Alshawsh MA, Chik Z, Mohamed Z. Effect of catha edulis (khat) on pancreatic functions in streptozotocin-induced diabetes in male sprague-Dawley rats. Exp Anim. 2018 [Nov 1];67(4):517–26. doi:10.1538/expanim.18-0057.
   PubMed Web of Science ®Google Scholar
• Dhaliwal J, Dhaliwal N, Akhtar A, Kuhad A, Chopra K. Beneficial effects of ferulic acid alone and in combination with insulin in streptozotocin induced diabetic neuropathy in Sprague Dawley rats. Life Sci. 2020;255:117856. Aug 15. doi:10.1016/j.lfs.2020.117856.
   PubMed Web of Science ®Google Scholar
• Lenzen S. 2007. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 51(2):216–26. doi:10.1007/s00125-007-0886-7
   PubMed Web of Science ®Google Scholar
• Wang X, Pan J, Liu D, Zhang, M, Li, X, Tian, J, Liu , M, Jin, T, An, F . Nicorandil alleviates apoptosis in diabetic cardiomyopathy through PI3K/Akt pathway. J Cell Mol Med. 2019;23(8):5349–59. doi:10.1111/jcmm.14413.
   PubMed Web of Science ®Google Scholar
• Kuno Y, Iyoda M, Shibata T, Hirai Y, Akizawa T. 2011. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent otsuka long-evans tokushima fatty rats. Br J Pharmacol. 162(6):1389–400. doi:10.1111/j.1476-5381.2010.01149.x
   PubMed Web of Science ®Google Scholar
• Baumeier C, Schlüter L, Saussenthaler S, Laeger T, Rödiger M, Alaze SA, Fritsche L, Häring HU, Stefan N, Fritsche A, et al. 2017. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab. 6(10):1254–63. doi:10.1016/j.molmet.2017.07.016
   PubMed Web of Science ®Google Scholar
• Lopez-Mejia IC, Lagarrigue S, Giralt A, Martinez-Carreres L, Zanou N, Denechaud PD, Castillo-Armengol J, Chavey C, Orpinell M, Delacuisine B, et al. 2017. CDK4 phosphorylates ampkα2 to inhibit its activity and repress fatty acid oxidation. Mol Cell. 68(2):336–349.e6. doi:10.1016/j.molcel.2017.09.034
   PubMed Web of Science ®Google Scholar
• Trammell AW, Hemnes AR, Tseng V, Shah AJ, Phillips LS, Hart CM. Influence of body weight and diabetes mellitus in patients with pulmonary hypertension. Am J Cardiol. 2020;134:130–37. 10.1016/j.amjcard.2020.07.062.
   PubMed Web of Science ®Google Scholar
• Cohen JL, Nees SN, Valencia GA, Rosenzweig EB, Krishnan US. Sildenafil use in children with Pulmonary Hypertension. J Pediatr. 2019;205:29–34.e1. 10.1016/j.jpeds.2018.09.067.
   PubMed Web of Science ®Google Scholar
• Felix NS, de Mendonça L, Braga CL, da Silva JS, Samary CDS, Vieira JB, Cruz F, Rocha NN, Zapata-Sudo G, Rocco PRM, et al. 2019. Effects of the FGF receptor-1 inhibitor, infigratinib, with or without sildenafil, in experimental pulmonary arterial hypertension. Br J Pharmacol. 176(23):4462–73. doi:10.1111/bph.14807
   PubMed Web of Science ®Google Scholar
• Sharma JN, Narayanan P. The kallikrein-kinin pathways in hypertension and diabetes. Prog Drug Res. 2014;69:15–36.
   PubMedGoogle Scholar
• Yu C, Chen S, Wang X, Wu G, Zhang Y, Fu C, Hu C, Liu Z, Luo X, Wang J, et al. Exposure to maternal diabetes induces endothelial dysfunction and hypertension in adult male rat offspring. Microvasc Res. 2021;133:104076. 10.1016/j.mvr.2020.104076.
   PubMed Web of Science ®Google Scholar
• Huang JX, Chen ZS, Zhang Y, Zhang K, Chen YY, Chen LM, Zhou WW. 2017. Establishment of rat model of type 2 diabetes complicated with hypertension. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 33(4):329–33. doi:10.12047/j.cjap.5501.2017.080
   PubMedGoogle Scholar
• CT K Jr, Morey TE, Lobato EB, Jm A Jr, Staples ED, Schofield RS, Hess PJ, Martin TD, Beaver TM. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg. 2007;83(1):68–71. doi:10.1016/j.athoracsur.2006.08.051. discussion 71.
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez JG, Moral-Sanz J, Frazziano G, Gomez-Villalobos MJ, Flores-Hernandez J, Monjaraz E, Cogolludo A, Perez-Vizcaino F. 2008. Diabetes induces pulmonary artery endothelial dysfunction by NADPH oxidase induction. Am J Physiol Lung Cell Mol Physiol. 295(5):L727–32. doi:10.1152/ajplung.90354.2008
   PubMed Web of Science ®Google Scholar
• Rosengarten B, Schermuly RT, Voswinckel R, Kohstall MG, Olschewski H, Weissmann N, Seeger W, Kaps M, Grimminger F, Ghofrani HA. 2006. Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc Dis. 21(3):194–200. doi:10.1159/000090555
   PubMed Web of Science ®Google Scholar
• Sheng M, Lu H, Liu P, Li Y, Ravi H, Peng SL, Diaz-Arrastia R, Devous MD, Womack KB. 2017. Sildenafil improves vascular and metabolic function in patients with alzheimer’s disease. J Alzheimers Dis. 60(4):1351–64. doi:10.3233/JAD-161006
   PubMed Web of Science ®Google Scholar
• Wortel RC, Mizrachi A, Li H, Markovsky E, Enyedi B, Jacobi J, Brodsky O, Cao J, Lippert AR, Incrocci L, et al. 2019. Sildenafil protects endothelial cells from radiation-induced oxidative stress. J Sex Med. 16(11):1721–33. doi:10.1016/j.jsxm.2019.08.015
   PubMed Web of Science ®Google Scholar
• Schultz J, Andersen A, Gade IL, Kjaergaard B, Nielsen-Kudsk JE. 2020. Riociguat, sildenafil and inhaled nitric oxide reduces pulmonary vascular resistance and improves right ventricular function in a porcine model of acute pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 9(4):293–301. doi:10.1177/2048872619840772
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Natarajan R, Drake JI, Bogaard HJ. 2011. Right ventricle in pulmonary hypertension. Compr Physiol. 1(1):525–40. doi:10.1002/cphy.c090008
   PubMed Web of Science ®Google Scholar
• Guazzi M. 2018. Pulmonary hypertension and heart failure: a dangerous liaison. Heart Fail Clin. 14(3):297–309. doi:10.1016/j.hfc.2018.02.006
   PubMed Web of Science ®Google Scholar
• Hiram R, Naud P, Xiong F, Al-u’datt D, Algalarrondo V, Sirois MG, Tanguay JF, Tardif JC, Nattel S. 2019. Right atrial mechanisms of atrial fibrillation in a rat model of right heart disease. J Am Coll Cardiol. 74(10):1332–47. doi:10.1016/j.jacc.2019.06.066
   PubMed Web of Science ®Google Scholar
• Pinsky MR. 2016. The right ventricle: interaction with the pulmonary circulation [published correction appears in Crit Care. 2016 Nov 10;20(1):364]. Crit Care. 20(1):266. doi:10.1186/s13054-016-1440-0
   PubMedGoogle Scholar
• Li YL, Li YQ, Zeng FQ, Lin XY, Li XT, Ren XQ, Yang DL. 2021. Sildenafil improves right ventricular remodelling in monocrotaline-induced rats by decreasing myocardial apoptosis and activating peroxisome proliferator-activated receptors. J Pharm Pharmacol. 73(2):145–51. doi:10.1093/jpp/rgaa017
   PubMed Web of Science ®Google Scholar
• Vonk Noordegraaf A, Westerhof BE, Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. J Am Coll Cardiol. 2017;69(2):236–43. doi:10.1016/j.jacc.2016.10.047. PMID: 28081831.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Weir EK. 2020. Pulmonary arterial hypertension and sex in the right ventricle: it is an interesting picture! Am J Respir Crit Care Med. 202(7):928–29. doi:10.1164/rccm.202006-2147ED
   PubMed Web of Science ®Google Scholar
• Jasińska-Stroschein M, Owczarek J, Wesołowska A, Orszulak-Michalak D. 2014. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat. Acta Pharm. 64(3):345–53. doi:10.2478/acph-2014-0029
   PubMed Web of Science ®Google Scholar
• Yoshiyuki R, Tanaka R, Fukushima R, Machida N. 2016. Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension. Exp Anim. 65(3):215–22. doi:10.1538/expanim.15-0070
   PubMed Web of Science ®Google Scholar
• Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. 2020. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc Disord. 20(1):408. doi:10.1186/s12872-020-01671-2
   PubMed Web of Science ®Google Scholar
• Monzo L, Reichenbach A, Al-Hiti H, Borlaug BA, Havlenova T, Solar N, Tupy M, Ters J, Kautzner J, Melenovsky V. 2021. Acute unloading effects of sildenafil enhance right ventricular-pulmonary artery coupling in heart failure. J Card Fail. 27(2):224–32. doi:10.1016/j.cardfail.2020.11.007
   PubMed Web of Science ®Google Scholar
• Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, et al. 2007. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 116(3):238–48. doi:10.1161/CIRCULATIONAHA.106.655266
   PubMed Web of Science ®Google Scholar
• Andersson KE. 2018. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 175(13):2554–65. doi:10.1111/bph.14205
   PubMed Web of Science ®Google Scholar
• Sharma M, Suero-Abreu GA, Neupane R, Kim B. Role of phosphodiesterase-5 inhibitors in acute right ventricular failure due to pulmonary embolism. Am J Case Rep. 2019;20:1144–47. 10.12659/AJCR.915832.
   PubMed Web of Science ®Google Scholar
• Lu Z, Xu X, Hu X, Lee S, Traverse JH, Zhu G, Fassett J, Tao Y, Zhang P, Dos Remedios C, et al. 2010. Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation. 121(13):1474–83. doi:10.1161/CIRCULATIONAHA.109.906818
   PubMed Web of Science ®Google Scholar
• Shan X, Margulies KB. 2011. Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models. PLoS One. 6(5):e19922. doi:10.1371/journal.pone.0019922
   PubMed Web of Science ®Google Scholar
• Garcia AM, Nakano SJ, Karimpour-Fard A, Nunley K, Blain-Nelson P, Stafford NM, Stauffer BL, Sucharov CC, Miyamoto SD. 2018. Phosphodiesterase-5 is elevated in failing single ventricle myocardium and affects cardiomyocyte remodeling in vitro. Circ Heart Fail. 11(9):e004571. doi:10.1161/CIRCHEARTFAILURE.117.004571
   PubMed Web of Science ®Google Scholar
• Howarth FC, Jacobson M, Shafiullah M, Adeghate E. 2008. Long-term effects of type 2 diabetes mellitus on heart rhythm in the Goto-Kakizaki rat. Exp Physiol. 93(3):362–69. doi:10.1113/expphysiol.2007.040055
   PubMed Web of Science ®Google Scholar
• Howarth FC, Jacobson M, Shafiullah M, Ljubisavljevic M, Adeghate E. 2011. Heart rate, body temperature and physical activity are variously affected during insulin treatment in alloxan-induced type 1 diabetic rat. Physiol Res. 60(1):65–73. doi:10.33549/physiolres.931984
   PubMed Web of Science ®Google Scholar
• Aggarwal Y, Das J, Mazumder PM, Kumar R, Sinha RK. 2021. Heart rate variability time domain features in automated prediction of diabetes in rat. Phys Eng Sci Med. 44(1):45–52. doi:10.1007/s13246-020-00950-8
   PubMedGoogle Scholar
• Turker Y, Aslantas Y, Aydin Y, Demirin H, Kutlucan A, Tibilli H, Turker Y, Ozhan H. 2013. Heart rate variability and heart rate recovery in patients with type 1 diabetes mellitus. Acta Cardiol. 68(2):145–50. doi:10.1080/ac.68.2.2967271
   PubMed Web of Science ®Google Scholar
• Wang XD, Zhou L, Zhu CY, Chen B, Chen Z, Wei L. Autonomic function as indicated by heart rate deceleration capacity and deceleration runs in type 2 diabetes patients with or without essential hypertension. Clin Interv Aging. 2018;13:1169–76. 10.2147/CIA.S149920.
   PubMed Web of Science ®Google Scholar
• Sydó N, Sydó T, Merkely B, Carta KG, Murphy JG, Lopez-Jimenez F, Allison TG. 2016. Impaired heart rate response to exercise in diabetes and its long-term significance. Mayo Clin Proc. 91(2):157–65. doi:10.1016/j.mayocp.2015.10.028
   PubMed Web of Science ®Google Scholar
• Martinez PF, Okoshi MP. 2018. Heart rate variability in coexisting diabetes and hypertension. Arq Bras Cardiol. 111(1):73–74. doi:10.5935/abc.20180118
   PubMed Web of Science ®Google Scholar
• Cassidy S, Vaidya V, Houghton D, Zalewski P, Seferovic JP, Hallsworth K, MacGowan GA, Trenell MI, Jakovljevic DG. 2019. Unsupervised high-intensity interval training improves glycaemic control but not cardiovascular autonomic function in type 2 diabetes patients: a randomised controlled trial. Diab Vasc Dis Res. 16(1):69–76. doi:10.1177/1479164118816223
   PubMed Web of Science ®Google Scholar
• Pirintr P, Saengklub N, Limprasutr V, Sawangkoon S, Kijtawornrat A. 2017. Sildenafil improves heart rate variability in dogs with asymptomatic myxomatous mitral valve degeneration. J Vet Med Sci. 79(9):1480–88. doi:10.1292/jvms.17-0016
   PubMed Web of Science ®Google Scholar
• Akinlade OM, Owoyele BV, Soladoye OA. 2020. Heart rate variability indices, biomarkers, and cardiac nerve density: independent surrogate markers for diagnosis of diabetic cardiac autonomic neuropathy in type 2 diabetes mellitus animal model. Int J Health Sci. 14(6):24–30.
   Google Scholar
• Gardim CB, de Oliveira BA, Bernardo AF, Gomes RL, Pacagnelli FL, Lorençoni RM, Vanderlei LC. 2014. Heart rate variability in children with type 1 diabetes mellitus. Rev Paul Pediatr. 32(2):279–85. doi:10.1590/0103-0582201432215513
   PubMedGoogle Scholar
• Li X, Jiang YH, Jiang P, Lin HQ, Yang JL, Ma DF, Wang X, Yang CH. 2015. Analysis of heart rate variability and cardiac autonomic nerve remodeling in streptozotocin-induced diabetic rats. Exp Clin Endocrinol Diabetes. 123(5):272–81. doi:10.1055/s-0035-1547258
   PubMed Web of Science ®Google Scholar
• Kristiansen E, Wanby P, Åkesson K, Blomstrand P, Brudin L, Thegerström J. 2020. Assessing heart rate variability in type 1 diabetes mellitus-Psychosocial stress a possible confounder. Ann Noninvasive Electrocardiol. 25(5):e12760. doi:10.1111/anec.12760
   PubMed Web of Science ®Google Scholar
• Eckstein ML, Moser O, Tripolt NJ, Pferschy, PN, Obermayer, AAM, Kojzar, H, Mueller, A, Abbas, F, Sourij, C, Sourij, H . Rapid glucose rise reduces heart rate variability in adults with type 1 diabetes: a prospective secondary outcome analysis. Diabetes Obes Metab. 2021;23(7):1681–84. doi:10.1111/dom.14287.
   PubMed Web of Science ®Google Scholar
• Saberi FS, Namazi SN, Bakhtiarian A, Ghazi KM, Karimi MY, Ranjbar A, Safa M, Hosseini A. 2018. Sildenafil protective effects on high glucose-induced neurotoxicity in PC12 cells: the role of oxidative stress, apoptosis, and inflammation pathways in an in vitro cellular model for diabetic neuropathy. Neurol Res. 40(8):624–36. doi:10.1080/01616412.2018.1458813
   PubMed Web of Science ®Google Scholar
• Wang L, Chopp M, Szalad A, Jia L, Lu X, Lu M, Zhang L, Zhang Y, Zhang R, Zhang ZG. 2015. Sildenafil ameliorates long term peripheral neuropathy in type II diabetic mice. PLoS One. 10(2):e0118134. doi:10.1160/TH13-02-0097
   PubMed Web of Science ®Google Scholar
• Hong-liang Z, Qin L, Zhi-hong L, Zhi-hui Z, Chang-ming X, Xin-hai N, Jian-guo H, Ying-jie W, Shu Z. 2009. Heart rate-corrected QT interval and QT dispersion in patients with pulmonary hypertension. Wien Klin Wochenschr. 121(9–10):330–33. doi:10.1007/s00508-009-1184-9
   PubMed Web of Science ®Google Scholar
• Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, Archer SL. 2013. QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol. 167(3):669–76. doi:10.1016/j.ijcard.2012.03.071
   PubMed Web of Science ®Google Scholar
• Zaky A, Zafar I, Masjoan-Juncos JX, Husain M, Mariappan N, Morgan CJ, Hamid T, Frölich MA, Ahmad S, Ahmad A. Echocardiographic, biochemical, and electrocardiographic correlates associated with progressive pulmonary arterial hypertension. Front Cardiovasc Med. 2021;8:705666. 10.1538/expanim.18-0057.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takase B, Yao T, Ishihara M. 2013. Right ventricular electrical remodeling and arrhythmogenic substrate in rat pulmonary hypertension. Am J Respir Cell Mol Biol. 49(3):426–36. doi:10.1165/rcmb.2012-0089OC
   PubMed Web of Science ®Google Scholar
• Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, et al. 2010. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl). 88(1):47–60. doi:10.1007/s00125-007-0886-7
   PubMed Web of Science ®Google Scholar
• Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, Dobric M, Trenell MI, Lalic N, Seferovic PM, et al. 2016. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol. 53(5):737–44. doi:10.1007/s00592-016-0864-y
   PubMed Web of Science ®Google Scholar
• Karpuz D, Hallioglu O, Toros F, Tasdelen B. 2017. The effect of metilpheniydate, risperidone and combination therapy on ECG in children with attention-deficit hyperactivity disorder. Journal of Electrocardiology. 50(4):410–15. doi:10.1016/j.jelectrocard.2017.02.012
   PubMed Web of Science ®Google Scholar